Drug Discovery on Chemistry of Medicinal Drug

Presented by:LORRAINE S. RIVERAMSPharm (Student)

wwwwww Dengue vaccine research

Dengue is a mosquito-borne flavivirus disease that has spread to most tropical and many subtropical areas.

The disease is caused by four closely related viruses, the Dengue viruses 1-4.

Dengue Vaccine Research

There are no specific dengue therapeutics and prevention is currently limited to vector control measures.

A dengue vaccine would therefore represent a major advance in the control of the disease.

Status of Vaccine Development

The first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was first registered in Mexico in December, 2015.

Status of Vaccine Development

CYD-TDV is a live recombinant tetravalent dengue vaccine that has been evaluated as a 3-dose series on a 0/6/12 month schedule in Phase III clinical studies.

It has been registered for use in individuals 9-45 years of age living in endemic areas.

Current Status of Dengue Vaccine Development

One dengue vaccine has been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur.

Approximately five additional dengue vaccine candidates are in clinical development, with two candidates (developed by Butantan and Takeda) expected to begin Phase III trials in early 2016.

WHO’s Recommendations Related to CYD-TDV

The WHO Strategic Advisory Group of Experts (SAGE) on Immunization is currently reviewing the evidence and will advise WHO (likely in April 2016) on recommended use of a dengue vaccine.

WHO’s Recommendations Related to CYD-TDV

Main considerations include vaccine safety, vaccine efficacy, disease burden, programmatic suitability, including dose scheduling, and cost-effectiveness

WHO’s Recommendations Related to CYD-TDV

WHO guidance on public health use will only be issued following licensure of the vaccine by a functional NRA meeting certain criteria as assessed by WHO and the SAGE assessment.

THANK YOU!!!